Author

B. Faubert

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3 Biochemistry· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 4 Approach:experimental assay· 3 Assay:metabolomics· 3 Research Focus:cancer & tumor microenvironment· 2 Research Focus:metabolism & bioenergetics· 2 Assay:bulk RNA-seq· 1 Organism:mouse· 1 Approach:statistical model· 1

Frequent Co-Authors

R. J. DeBerardinis· 4 shared B. Ko· 3 shared F. Cai· 3 shared L. Cai· 3 shared C. Yang· 2 shared J. Kim· 2 shared J. Minna· 2 shared L. G. Zacharias· 2 shared

Activity by Year

2019-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 37 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersCancer Biology

R. J. DeBerardinis

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Electron transport inhibition increases cellular dependence on purine transport and salvage

Z. Wu, D. Bezwada, R. C. Harris, C. Pan, P. T. Nguyen, B. Faubert, L. Cai, F. Cai, H. S. Vu, H. Chen, M. Martin-Sandoval, D. Do, W. Gu, Y. Zhang, B. Ko, , R. J. DeBerardinis

This study shows that ETC inhibition in cancer cells increases reliance on purine salvage and transport, revealing a metabolic vulnerability in tumors with low oxidative metabolism.

bioRxiv · May 11, 2023Biochemistry

In-vivo characterization of glutamine metabolism identifies therapeutic targets in clear cell renal cell carcinoma

A. Kaushik, L. K. Burroughs, A. Tarangelo, M. Ragavan, C.-Y. Wu, X. Li, K. Ahumada, V. T. Tcheuyap, F. Saatchi, Q. Do, C. Yong, T. Rosales, C. Stevens, A. D. Rao, B. Faubert, , R. J. DeBerardinis

The paper identifies multiple glutamine metabolism pathways in ccRCC tumorgrafts and shows that targeting amidotransferase activity reduces tumor growth.

bioRxiv · Oct 31, 2022Cancer Biology

The hexosamine biosynthesis pathway is a targetable liability in lung cancers with concurrent KRAS and LKB1 mutations.

J. Kim, F. Cai, B. Ko, C. Yang, H. M. Lee, N. Muhammad, K. Li, M. Haloul, W. Gu, B. Faubert, A. K. Kaushik, L. Cai, S. Kasiri, U. Marriam, K. Nham, , R. J. DeBerardinis

The paper identifies the hexosamine biosynthesis pathway as a metabolic vulnerability in KRAS/LKB1 mutant lung cancers and shows GFPT2 inhibition reduces tumor growth.

bioRxiv · Apr 13, 2020 · PreprintCancer Biology

METABOLIC DIVERSITY IN HUMAN NON-SMALL CELL LUNG CANCER CELLS

P.-H. CHEN, L. Cai, C. Yang, J. Kim, B. Faubert, L. Boroughs, B. Ko, J. Sudderth, E. A. McMillan, L. Girard, M. Peyton, K. Huffman, M. D. Shields, D. Shames, H. S. Kim, , R. J. DeBerardinis

The paper quantifies metabolic features in NSCLC cell lines to explore associations between metabolism and other cell-autonomous processes.

bioRxiv · Mar 11, 2019Cancer Biology